Treatments for corneal neovascularization: A review

Cornea

Volumn 30, Issue 8, 2011, Pages 927-938

  Gupta, Deepak ^a   Illingworth, Chris ^a  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Avastin; Bevacizumab; Corneal Neovascularization; Photodynamic therapy

Indexed keywords

BEVACIZUMAB; CORTISONE; CYCLOSPORIN; DEXAMETHASONE; DICLOFENAC; FLUORESCEIN; FLURBIPROFEN; HYDROCORTISONE; INDOMETACIN; KETOROLAC; MEDROXYPROGESTERONE; METHYLPREDNISOLONE; NEPAFENAC; PHOTOFRIN II; PREDNISOLONE; RADIUM; ROSE BENGAL; SMALL INTERFERING RNA; STRONTIUM 90; TICABESONE PROPIONATE; TRIAMCINOLONE; VASCULOTROPIN; VERTEPORFIN;

ANGIONEUROTIC EDEMA; BACKACHE; CAUTERIZATION; CORECTOPIA; CORNEA NEOVASCULARIZATION; CORNEA TRANSPLANTATION; DIATHERMY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; INCIDENCE; IRIS ATROPHY; IRIS BURN; IRIS DISEASE; IRITIS; KERATECTOMY; LASER SURGERY; PATHOGENESIS; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PHOTOTOXICITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SKIN MANIFESTATION;

EID: 85027922990     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e318201405a     Document Type: Review

References (258)

1. Roodhooft JMJ. Leading causes of blindness worldwide. Bull Soc Belge Ophtalmol. 2002;283:19-25.
2. Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol. 1998;43:245-269. (Pubitemid 28558273)
3. Roth HW. The etiology of ocular irritation in soft lens wearers: distribution in a large clinical sample. Contact Intraocul Lens Med J. 1978;4:38-37.
4. Cursiefen C, Kuchle M, Naumann GOH. Angiogenesis in corneal disease: histopathologic evaluation of 254 human corneal buttons with neovascularization. Cornea. 1998;17:611-613. (Pubitemid 28511907)
5. Cursiefen C, Hofmann-Rummelt C, Kuchle M, et al. Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation. Br J Ophthalmol. 2003;87:101-106. (Pubitemid 36071788)
6. Usui T, Sugisaki K, Iriyama A, et al. Inhibition of corneal neovascularization by blocking the angiotensin type 1 receptor. Invest Ophthalmol Vis Sci. 2008;49:4370-4376.
7. Cursiefen C, Chen L, Reza Dana M, et al. Corneal lymphangiogenesis: evidence, mechanisms and implications for corneal transplant immunology. Cornea. 2003;22:273-281. (Pubitemid 36359171)
8. Cursiefen C, Masli S, Ng TF, et al. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci. 2004;45:1117-1124. (Pubitemid 38869016)
9. Lindstrom RL. Advances in corneal transplantation. N Engl J Med. 1986; 315:1-2.
10. Qazi Y, Wong G, Monson B, et al. Corneal transparency: genesis, maintenance and dysfunction. Brain Res Bull. 2009;27;198-210.
11. Niederkorn JY. Immune privilege and immune regulation in the eye. Adv Immunol. 1990;48:191-226. (Pubitemid 20210190)
12. Panda A, Vanathi M, Kumar A, et al. Corneal graft rejection. Surv Ophthalmol. 2007;52:375-396. (Pubitemid 46901076)
13. Pillai CT, Dua HS, Hossain P. Fine needle diathermy occlusion of corneal vessels. Invest Ophthalmol Vis Sci. 2000;41:2148-2153. (Pubitemid 30450986)
14. Chang JH, Gabison EE, Kato T, et al. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12:242-249. (Pubitemid 32751680)
15. Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature. 2006;443:993-997. (Pubitemid 44646176)
16. Stuart PM, Pan F, Plambeck S, et al. FasL-Fas interactions regulate neovascularization in the cornea. Invest Ophthalmol Vis Sci. 2003;44: 4010-4015.
17. Mwaikambo BR, Sennlaub F, Ong H, et al. Activation of CD36 inhibits and induces regression of inflammaotry corneal neovascularization. Invest Ophthalmol Vis Sci. 2006;47:4356-4364. (Pubitemid 46579359)
18. Bellner L, Vitto M, Patil KA, et al. Exacerbated corneal inflammation and neovascularization in the HO-2 null mice is ameliorated by biliverdin. Exp Eye Res. 2008;87:268-278.
19. Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006;104:264-302. (Pubitemid 46495064)
20. BenEzra D, Griffin BW, Maftzir G, et al. Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization. Invest Ophthalmol Vis Sci. 1997;38:1954-1962. (Pubitemid 27407514)
21. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-36.
22. Kaminska G, Niederkorn J. Spontaneous corneal neovascularization in nude mice: local imbalance between angiogenic and antiangiogenic factors. Invest Ophthalmol Vis Sci. 1993;34:222-230. (Pubitemid 23045120)
23. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267: 10931-10934.
24. Kwitko S, Marinho D, Barcaro S, et al. Allograft conjunctival transplantation for bilateral ocular surface disorders. Ophthalmology. 1995;102:1020-1025.
25. BenEzra D. Neovasculogensis: triggering factors and possible mechanisms. Surv Ophthalmol. 1979;24:167-176.
26. Burger PC, Chandler DB, Klintworth GK. Experimental corneal neovascularization: biomicroscopic, angiographic and morphologic correlation. Cornea. 1985;4:35-41. (Pubitemid 16116837)
27. Cogan DG. Corneal neovascularization. Invest Ophthalmol Vis Sci. 1962;1:253-261.
28. Yayli V, Ohat T, Kaufman SC, et al. In vivo confocal imaging of corneal neovascularization. Cornea. 1998;17:646-653. (Pubitemid 28511912)
29. Scroggs MW, Proia AD, Smith CF, et al. The effect of total-body irradiation on corneal neovascularization in the Fischer 344 rat after chemical cauterization. Invest Ophthalmol Vis Sci. 1991;32:2105-2111.
30. Klintworth GK. Corneal Angiogenesis: A Comprehensive Critical Review. New York, NY: Springer-Verlag; 1991:5-10.
31. Fromer CH, Klintworth GK. An evaluation of the role of leukocytes in the pathogenesis of experimentally induced corneal neovascularization. Comparison of experimental models of corneal neovascularization. Am J Pathol. 1975;79:537-554.
32. van Haeringen NJ, Bolkova A, Oosterhuis JA, et al. Enzyme activities in the rabbit cornea during immunogenic keratitis. Graefes Arch Clin Exp Ophthalmol. 1986;224:288-289.
33. Kato T, Kure T, Chang JH, et al. Diminished corneal angiogenesis in gelatinase A-deficient mice. FEBS Lett. 2001;508:187-190. (Pubitemid 33079244)
34. Ma DH, Chen JK, Kim WS, et al. Expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in inflammation-induced corneal neovascularization. Ophthalmic Res. 2001;33:353-362. (Pubitemid 34015800)
35. Samolov B, Steen B, Seregard S, et al. Delayed inflammation-associated corneal neovascularization in MMP-2-defiecient mice. Exp Eye Res. 2005;80:159-166.
36. Ambati BK, Joussen AM, Kuziel WA, et al. Inhibition of corneal neovascularization by genetic ablation of CCR2. Cornea. 2003;22: 465-467. (Pubitemid 36759041)
37. Ahmad N, Mukhtar H. Solid mechanisms of photodynamic therapyinduced cell death. Methods Enzymol. 2000;319:342-348.
38. Zheng M, Deshpande S, Lee S, et al. Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J Virol. 2001;75:9828-9835. (Pubitemid 32900118)
39. Alldredge OC, Krachmer JH. Clinical types of corneal transplant rejection: their manifestations, frequency, preoperative correlates, and treatment. Arch Ophthalmol. 1981;99:599-604. (Pubitemid 11106030)
40. Dana MR, Streilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci. 1996;37:2485-2494. (Pubitemid 26391286)
41. Hossain P. Biomarkers for corneal graft rejection? Eye. 2009;23:247.
42. Maguire MG, Stark WJ, Gottsch JD, et al. Risk factors for corneal graft failure and rejection in the Collaborative Corneal Transplantation Studies. Ophthalmology. 1994;101:1536-1547. (Pubitemid 24347052)
43. Mayer DJ, Casey TA. Reducing the risk of corneal graft rejection. A comparison of different methods. Cornea. 1987;6:261-268. (Pubitemid 18005954)
44. Price FW, Whitson WE, Johns S, et al. Risk factors for corneal graft failure. J Refract Surg. 1996;12:134-143.
45. Sellami D, Abid S, Bouaouaja G, et al. Epidemiology and risk factors for corneal graft rejection. Transplant Proc. 2007;39:2609-2611. (Pubitemid 47588385)
46. The Collaborative Corneal Transplant Studies Research Group. The Collaborative Corneal Transplantation Studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal tranplantation. Arch Ophthalmol. 1992;110:1392-1403.
47. Vail A, Bradley A, Easty D, et al. Cornea graft survival and visual outcome. Ophthalmology. 1994;101:120-127.
48. Vail A, Gore SM, Bradley BA, et al. Corneal transplantation in the United Kingdom and Republic of Ireland. Br J Ophthalmol. 1993;77: 650-656. (Pubitemid 23298387)
49. Bishop VLM, Robinson LP, Wechsler AW, et al. Corneal graft survival: a retrospective Australian study. Aust N Z J Ophthalmol. 1986;14: 133-138.
50. Mader TH, Stutling RD. The high-risk penetrating keratoplasty. Ophthalmol Clin North Am. 1991;4:411-426.
51. Volker-Dieben HJ, D'Amaro J, Kok-Van Alphen CC. Hierarchy of prognostic factors for corneal allograft survival. Aust N Z J Ophthalmol. 1987;15:11-18. (Pubitemid 17109890)
52. Dana MR, Schaumberg DA, Kowal VO, et al. Corneal neovascularization after penetrating keratoplasty. Cornea. 1995;14:604-609.
53. Hill JC. High risk corneal grafting. Br J Ophthalmol. 2002;86:945. (Pubitemid 34953600)
54. D'Amaro J, Völker-Dieben HJ, Kruit PJ, et al. Influence of pretransplant sensitization on the survival of corneal allografts. Transplant Proc. 1991; 23:368-372.
55. Hill JC. Immunosuppression in corneal transplantation. Eye. 1995;9: 247-253.
56. Regina M, Zimmerman R, Malik G, et al. Lymphangiogenesis concurrent with haemangiogenesis in the human cornea. Clin Exp Ophthalmol. 2007;35:541-544. (Pubitemid 47337971)
57. Kruse FE, Joussen AM, Rohrschneider K, et al. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol. 1998;236:461-466. (Pubitemid 28269042)
58. Lavergne G, Colmant IA. Comparative study of the action of thiotepa and triamcinolone on corneal vascularization in rabbits. Br J Ophthalmol. 1964;48:416-422.
59. Ey RC, Hughes WF, Bloome MA, et al. Prevention of corneal vascularization. Am J Ophthalmol. 1968;66:1118-1131.
60. Mayer W. Cryotherapy in corneal vascularization. Arch Ophthalmol. 1967;77:637-641.
61. Reed JW, Fromer C, Klintworth GK. Induced corneal vascularization remission with argon laser therapy. Arch Ophthalmol. 1975;93: 1017-1019.
62. Leigh AG. Treatment of gross corneal opacificaiton by lamellar and annular lamellar keratoplasty. Br J Ophthalmol. 1955;39:641-646.
63. Ainslie D, Snelling MD, Ellis RE. Treatment of corneal vascularization by strontium 90 beta plaque. Clin Symp. 1962;13:29.
64. Ainslie D, Snelling MD. Postoperative irradiation of corneal grafts. Its possible effect on the immunological reaction. Lancet. 1961;2:954-956.
65. Duggan HE. Results using the strontium-90 beta-ray applicator on eye lesions. J Can Assoc Radiol. 1966;17:132-137.
66. Faser H, Naunton WJ. Treatment of non-malignant corneal conditions with radioactive isotopes: a 5-year survery. Br J Ophthalmol. 1961;45: 358-364.
67. Freidell HL, Thomas CI, Krohmer JS. An evaluation of the clinical use of strontium 90 beta-ray applicator with a review of the underlying principles. Am J Roentgenol Radium Ther Nucl Med. 1954;71:25-39.
68. Leahy BD. Beta radiation in ophthalmology. Am J Ophthalmol. 1960;49: 7-29.
69. Lederman M. Radiotherapy of non-malignant diseases of the eye. Br J Ophthalmol. 1957;41:1-19.
70. Naunton WJ. Treating non-malignant corneal conditions by radiotherapy. Nurs Times. 1974;70:1149.
71. Kirwan JF, Constable PH, Murdoch IE, et al. Beta radiation: new uses for an old treatment: a review. Eye. 2003;17:207-215. (Pubitemid 36410740)
72. Barron A, Mc Donald JE, Hughes WF. Long-term complications of betaradiation therapy in ophthalmology. Trans Am Ophthalmol Soc. 1970;68: 113-128.
73. McMahon JM. The long-term effects of experimental beta-radiation therapy on the human cornea. Con Lens Anterior Eye. 2007;30:249-253. (Pubitemid 47289252)
74. Wilson F. Clinical and experimental experiences with beta irradiation of the eye. Trans Am Ophthalmol Soc. 1959;LVI:655-723.
75. Boneham GC, Collin HB. Steroid inhibition of limbal blood and lymphatic vascular cell growth. Curr Eye Res. 1995;14:1-10.
76. Manzano RP, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularization by bevacizumab (Avastin). Br J Ophthalmol. 2007;91:804-807. (Pubitemid 46846656)
77. Jones IS, Meyer K. Inhibition of vascularization of the rabbit cornea by local application of cortisone. Proc Soc Exp Biol Med. 1950;74: 102-104.
78. Mcdonald PR, Leopold IH, Vogel AW, et al. Hydrocortisone (compound F) in ophthalmology; clinical and experimental studies. AMA Arch Ophthalmol. 1953;49:400-412.
79. Michaelson IC, Gluecker L, Stieglitz E. Influence of low-voltage xradiation on inhibition and prevention of new vessels in cornea; comparison with influence of cortisone. AMA Arch Ophthalmol. 1954; 52:77-84.
80. Wybar KC, Campbell FW. The influence of cortisone on corneal vascularization in the guinea pig and rabbit. Trans Ophthalmol Soc UK. 1952;72:105-117.
81. Ahuja OP, Nema HV. Experimental corneal vacularization and its management. Am J Ophthalmol. 1966;62:707-710.
82. Mahoney JM, Waterbury LD. Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea. Curr Eye Res. 1985;4:531-535. (Pubitemid 15066517)
83. Nakao S, Hata Y, Miura M, et al. Dexamethasone inhibits interleukin- 1beta-induced corneal neovascularization: role of nuclear factor-kappaBactivated stromal cells in inflammatory angiogenesis. Am J Pathol. 2007; 171:1058-1065. (Pubitemid 47441002)
84. Phillips K, Arffa R, Cintron C, et al. Effects of prednisolone and medroxyprogesterone on corneal wound healing, ulceration, and neovascularization. Arch Ophthalmol. 1983;101:640-643. (Pubitemid 13116481)
85. Robin JB, Regis-Pacheco LF, Kash RL, et al. The histopathology of corneal neovascularization. Inhibitor effects. Arch Ophthalmol. 1985; 103:284-287. (Pubitemid 15173974)
86. Chang CT, Chen YL, Lee SH, et al. The inhibition of prostaglandin E1- induced corneal neovascularization by steroid eye drops. J Formos Med Assoc. 1989;88:707-711.
87. Crabb CV. Endocrine influences on ulceration and regeneration in the alkali-burned cornea. Arch Ophthalmol. 1977;95:1866-1870. (Pubitemid 8205938)
88. Lass JH, Berman MB, Campbell RC, et al. Treatment of experimental herpetic interstitial keratitis with medroxyprogesterone. Arch Ophthalmol. 1980;98:520-527. (Pubitemid 10133657)
89. Athanasiadis Y, Novitskaya E, Nithyanandrajah GA, et al. Subconjunctival triamcinolone for the treatment of corneal graft rejection and new vessels. Cont Lens Anterior Eye. 2009;32:31-32.
90. Aydin E, Kivilcim M, Peyman GA, et al. Inhibition of experimental angiogenesis of cornea by various doses of doxycycline and combination of triamcinolone acetonide with low-molecular-weight heparin and doxycycline. Cornea. 2008;27:446-453. (Pubitemid 351591483)
91. Ebrabem Q, Minamoto A, Hoppe G, et al. Triamcinolone acetonide inhibits IL-6- and VEGF-induced angiogenesis downstream of the IL-6 and VEGF receptors. Invest Ophthalmol Vis Sci. 2006;47:4935-4941. (Pubitemid 46586396)
92. Murata M, Shimizu S, Horichu S, et al. Inhibitory effect of triamcinolone acetonide on corneal neovascularization. Graefes Arch Clin Ophthalmol. 2006;244:205-209.
93. Riazi-Esfahani M, Peyman GA, Aydin E, et al. Prevention of corneal neovascularization: evaluation of various commercially available compounds in an experimental rat model. Cornea. 2006;25:801-805. (Pubitemid 44657255)
94. Leopold IH, Purnell JE, Cannon EJ, et al. Local and systemic cortisone in ocular disease. Am J Ophthalmol. 1951;34:361-371.
95. Klintworth GK. Corneal Angiogenesis: A Comprehensive Critical Review. New York, NY: Springer-Verlag; 1991:16.
96. Rhen T, Cidlowski JA. Anti-inflammatory action of glucocorticoids- new mechanisms for old drugs. N Engl J Med. 2005;353:1711-1723.
97. Fromer CH, Klintworth GK. An evaluation of the role of leukocytes in the pathogenesis of experimentally induced corneal vascularization. II. Studies on the effect of leukocytic elimination on corneal vascularization. Am J Pathol. 1975;81:531-544.
98. Schleimer RP, Freeland HS, Peters SP, et al. An assessment of the effects of glucocorticoids on degranulation, chemotaxis, binding to vascular endothelium and formation of leukotriene B4 by purified human neutrophils. J Pharmacol Exp Ther. 1989;250:598-605. (Pubitemid 19216145)
99. McNatt LG, Weimer JY, Clark AF. Angiostatic activity of steroids in the chick embryo CAM and the rabbit cornea models of neovascularization. J Ocul Pharmacol Ther. 1999;15:413-423. (Pubitemid 29480958)
100. Besedovsky H, del Rey A, Sorkin E, et al. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science. 1986;233: 652-654. (Pubitemid 16011614)
101. Beutler B, Krochin N, Milsark IW, et al. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science. 1986;232:977-980. (Pubitemid 16085400)
102. Hori Y, Hu DE, Yasui K, et al. Differential effects of angiostatic steroids and dexamethasone on angiogenesis and cytokine levels in rat sponge implants. Br J Pharmacol. 1996;118:1584-1591. (Pubitemid 26252648)
103. Snyder DS, Unanue ER. Corticosteroids inhibit murine macrophage Ia expression and interleukin 1 production. J Immunol. 1982;129: 1803-1805. (Pubitemid 12004324)
104. Waage A, Slupphaug G, Shalaby R. Glucocorticoids inhibit the production of IL6 from monocytes, endothelial cells and fibroblasts. Eur J Immunol. 1990;20:2439-2443.
105. Jørgensen KA, Stoffersen E. Hydrocortisone inhibits platelet prostaglandin and endothelial prostacyclin production. Pharmacol Res Commun. 1981;13:579-586. (Pubitemid 11089566)
106. Boggs DR, Athens JW, Cartwright GE, et al. The effect of adrenal glucocorticosteroids upon the cellular composition of inflammatory exudates. Am J Pathol. 1964;44:763-773.
107. Weissmann G. The role of lysosomes in inflammation and disease. Annu Rev Med. 1967;18:97-112.
108. Claman HN. Corticosteroids and lymphoid cells. N Engl J Med. 1972; 287:388-397.
109. Folkman J, Weisz PB, Joullié MM, et al. Control of angiogenesis with synthetic heparin substitutes. Science. 1989;243:1490-1493. (Pubitemid 19087138)
110. Lepri A, Benelli U, Bernardini N, et al. Effect of low molecular weight heparan sulphate on angiogenesis in the rat cornea after chemical cauterization. J Ocul Pharmacol. 1994;10:273-280. (Pubitemid 24119448)
111. Tommila P, Summanen P, Tervo T. Cortisone, heparin and argon laser in the treatment of corneal neovascularization. Acta Ophthalmol Suppl. 1987;182:89-92. (Pubitemid 18028390)
112. LiWW, Casey R, Gonzalez EM, et al. Angiostatic steroids potentiated by sulfated cyclodextrins inhibit corneal neovascularization. Invest Ophthalmol Vis Sci. 1991;32:2898-2905.
113. Sipos EP, Brem H. Local antiangiogenic brain tumor therapies. J Neurooncol. 2000;50:181-188. (Pubitemid 32166300)
114. Harada I, Kikuchi T, Shimomura Y, et al. The mode of action of antiangiogenic steroid and heparin. EXS. 1992;61:445-448.
115. Ingber DE, Madri JA, Folkman J. A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution. Endocrinology. 1986;119:1768-1775. (Pubitemid 17170550)
116. Blei F, Wilson EL, Migatti P, et al. Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J Cell Physiol. 1993;155: 568-578. (Pubitemid 23167401)
117. Nirankari VS, Baer JC. Corneal argon laser photocoagulation for neovascularization in penetrating keratoplasty. Ophthalmology. 1986;93: 1304-1309. (Pubitemid 16008994)
118. BenEzra D. Neovasculogenic ability of prostaglandins, growth factors, and synthetic chemoattractants. Am J Ophthalmol. 1978;86:455-461. (Pubitemid 9000001)
119. Frucht J, Zauberman H. Topical indomethacin effect on neovascularization of the cornea and on prostaglandin E2 levels. Br J Ophthalmol. 1984;68:656-659. (Pubitemid 15136079)
120. Ueda M, Sugatani J, Unezaki S, et al. Involvement of prostaglandin E2 in rabbit corneal injury by anterior segment ischaemia. Prostaglandins Leukot Essent Fatty Acids. 1997;57:285-291. (Pubitemid 27454263)
121. Deutsch TA, Hughes WF. Suppressive effects of indomethacin on thermally induced neovascularization of rabbit corneas. Am J Ophthalmol. 1979;87:536-540. (Pubitemid 9125613)
122. Takahashi K, Saishin Y, Saishin Y, et al. Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci. 2003;44:409-415. (Pubitemid 36134303)
123. Masferrer JL, Koki A, Seibert K. COX-2 inhibitors. A new class of antiangiogenic agents. Ann N Y Acad Sci. 1999;889:84-86. (Pubitemid 30040428)
124. Yamada M, Kawai M, Kawai Y, et al. The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat. Curr Eye Res. 1999;19:300-304.
125. Castro MR, Lutz D, Edelman JL. Effect of COX inhibitors on VEGFinduced retinal vascular leakage and experimental corneal and choroidal neovascularization. Exp Eye Res. 2004;79:275-285. (Pubitemid 39119416)
126. Duffin RM, Weissmann BA, Glasser DB, et al. Flurbiprofen in the treatment of corneal neovascularization induced by contact lenses. Am J Ophthalmol. 1982;93:607-614. (Pubitemid 12107411)
127. Katz HR, Aizuss DH, Mondino BJ. Inhibition of contact lens-induced corneal neovascularization in radial keratotomized rabbit eyes. Cornea. 1984;3:65-72. (Pubitemid 15176610)
128. Peyman GA, Kazi AA, Riazi-Esfahani M, et al. The effect of combinations of flurbiprofen, low molecular weight heparin, and doxycycline on the inhibition of corneal neovascularization. Cornea. 2006;25:582-585. (Pubitemid 44620104)
129. van Haeringen NJ, van Delft JL, Barthen ER, et al. Effect of indomethacin on immunogenic keratitis. Curr Eye Res. 1986;5:307-311. (Pubitemid 16106145)
130. Verby NLJ, van Haeringen NJ, de Jong PTVM.Modulators of immunogenic keratitis in rabbits by topical administration of inhibitors of lipoxygenase and cycloxygenase. Curr Eye Res. 1988;7:361.
131. Haynes WL, Hirakata A, Proia AD. Inhibition of corneal neovascularization in the rat by SK&F 86002, a dual inhibitor of arachadoic acid metabolism. Exp Eye Res. 1992;55:189-191.
132. Congdon NG, Schein OD, von Kulajta P, et al. Corneal complications associated with topical ophthalmic use of nonsteroidal anti-inflammatory drugs. J Cataract Refract Surg. 2001;27:622-631. (Pubitemid 33733436)
133. Flach AJ. Corneal melts associated with topically applied nonsteroidal anti-inflammatory drugs. Trans Am Ophthalmol Soc. 2001;99:205-210; discussion 210-212.
134. Guidera AC, Luchs JI, Udell IJ. Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. Ophthalmology. 2001;108:936-944. (Pubitemid 32374251)
135. Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998;39:18-22. (Pubitemid 28040457)
136. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol. 2007;18: 502-508. (Pubitemid 351339405)
137. Cursiefen C, Rummelt C, Küchle M. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea. 2000;19:526-533. (Pubitemid 30460894)
138. Gan L, Fagerhorn P, Palmblad J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovasculairzation and wound healing. Acta Ophthalmol Scand. 2004; 82:557-563. (Pubitemid 39386968)
139. Hosseini H, Nejabat M, Mehryar M, et al. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Experiment Ophthalmol. 2007;35:745-748. (Pubitemid 350090533)
140. Joussen AM, Poulaki V, Mitsiades N, et al. VEGF-dependent conjunctivalization of the corneal surface. Invest Ophthalmol Vis Sci. 2003;44:117-123. (Pubitemid 36134263)
141. Kim B, Tang Q, Niswas PS, et al. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes. Therpeutic strategy for herpetic stromal keratitis. Am J Pathol. 2004;165: 2177-2185. (Pubitemid 39578394)
142. Lai CM, Spilsbury K, Brankov M, et al. Inhibition of corneal neovascularization by recombinant adenovirus mediated antisense VEGF RNA. Exp Eye Res. 2002;75:625-634. (Pubitemid 36034627)
143. Murata M, Takanami T, Shimizu S, et al. Inhibition of ocular angiogenesis by diced small interfering RNAs (siRNAs) specific to vascular endothelial growth factor (VEGF). Curr Eye Res. 2006;31: 171-180.
144. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000;41:2514-2522. (Pubitemid 30624378)
145. Singh N, Amin S, Richter E, et al. Flt-1 intraceptors inhibit hypoxiainduced VEGF expression in vitro and corneal neovascularization in vivo. Invest Ophthalmol Vis Sci. 2005;46:1647-1652. (Pubitemid 44843599)
146. Bock F, König Y, Kruse F, et al. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2008; 246:281-284. (Pubitemid 351149633)
147. Brown LF, Detmar M, Claffey K, et al. Vascular permeability factor/ vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS. 1997;79:233-269.
148. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676. (Pubitemid 36749215)
149. Pawson T. Protein modules and signalling networks. Nature. 1995;373: 573-580.
150. Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase Cdependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene. 1999;18: 2221-2223.
151. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer. 2001;8: 161-173. (Pubitemid 32947638)
152. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593-4599. (Pubitemid 27441066)
153. Pytowski B, Goldman J, Persaud K, et al. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst. 2005;97:14-21.
154. Witte L, Hicklin DJ, Zhu Z, et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. 1998;17:155-161. (Pubitemid 28391949)
155. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 1995;92:10457-10461.
156. Singh N, Higgins E, Amin S, et al. Unique homologous siRNA blocks hypoxia-induced VEGF upregulation in human corneal cells and inhibits and regresses murine corneal neovascularization. Cornea. 2007;26: 65-72. (Pubitemid 46041566)
157. Fong TA, Shawyer LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999;59:99-106. (Pubitemid 29062964)
158. Strawn LM, McMahon G, App H, et al. Flk-1 as a target for tumor growth inhibition. Cancer Res. 1996;56:3540-3554.
159. Yatoh S, Kawakami Y, Imai M, et al. Effect of a topically applied neutralizing antibody against vascular endothelial growth factor on corneal allograft rejection of rat. Transplantation. 1998;66: 1519-1524. (Pubitemid 29014032)
160. Cursiefen C, Cao J, Chen L, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci. 2004; 45:2666-2673. (Pubitemid 38998863)
161. Bachmann BO, Bock F,Wiegand SJ, et al. Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol. 2008;126:71-77.
162. Barros LEM, Belfort R. The effects of subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea. An Acad Bras Cienc. 2007;79:389-394. (Pubitemid 47395344)
163. Chen WL, Lin CT, Lin NT, et al. Subconjuncitval injection of bevacizumab (Avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis. Invest Ophthalmol Vis Sci. 2009;50: 1659-1665.
164. Habot-Wilner Z, Barequet IS, Ivanir Y, et al. The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization. Acta Ophthalmol. 2010;88:862-867.
165. Han YS, Lee JE, Jung JW, et al. Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2009;247:541-548.
166. Hashemian MN, Moghimi S, Kiumehr S, et al. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats. Ophthalmic Res. 2009;42:90-95.
167. Hosseini H, Nejabat M. A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents. Med Hypotheses. 2007;68:799-801. (Pubitemid 46136794)
168. Hurmeric V, Mumcuoglu T, Erdurman C, et al. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs. Cornea. 2008;27:357-362. (Pubitemid 351440874)
169. Jing G.-L, Gao X.-W, Ren B, et al. The inhibitory action of bevacizumab on rat corneal neovascularization. Int J Ophthalmol. 2008;8:1955-1958.
170. Kim TI, Kim SW, Kim S, et al. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea. 2008;27:349-352. (Pubitemid 351440872)
171. Oh JY, Kim MK, Shin MS, et al. The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas. Curr Eye Res. 2009;34:85-91.
172. Papathanassiou M, Theodossiadis PG, Liarakos VS, et al. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol. 2008;145:424-431.
173. Yoeruek E, Spitzer MS, Tatar O, et al. Safety profile of bevacizumab on cultured human corneal cells. Cornea. 2007;26:977-982. (Pubitemid 47329805)
174. Yoeruek E, Ziemssen F, Henke-Fahle S, et al. Tübingen Bevacizumab Study Group. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol. 2008;86:322-328. (Pubitemid 351785106)
175. Awadein A. Subconjunctival bevacizumab for vascularized rejected corneal grafts. J Cataract Refract Surg. 2007;33:1991-1993. (Pubitemid 47615364)
176. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res. 2008;33:23-28. (Pubitemid 351156952)
177. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea. 2008;27:142-147. (Pubitemid 351158729)
178. Carrasco MA. Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis. Cornea. 2008;27:743-745.
179. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, et al. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, non-comparative study. Arch Ophthalmol. 2009;127: 381-389.
180. DeStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol. 2007;125:834-836. (Pubitemid 46919748)
181. Doctor PP, Bhat PV, Foster SF. Subconjunctival bevacizumab for corneal neovascularization. Cornea. 2008;27:992-995.
182. Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2007;245: 1577-1579. (Pubitemid 47423342)
183. Gerten G. Bevacizumab (Avastin) and argon laser to treat neovascularization in corneal transplant surgery. Cornea. 2008;27:1195-1199.
184. Harooni H, Reddy V, Root T, et al. Bevacizumab for graft rejection. Ophthalmology. 2007;114:1950.
185. Jacobs DS, Lim M, Carrasquillo KG, et al. Bevacizumab for corneal neovascularization. Ophthalmology. 2009;116:592-593; author reply 593-594.
186. Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology. 2008;115:e33-e38.
187. Mackenzie SE, Tucker WR, Poole TR. Bevacizumab (Avastin) for corneal neovascularization-corneal light shield soaked application. Cornea. 2009;28:246-247.
188. Qian CX, Bahar I, Levinger E, et al. Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization. Cornea. 2008;27:1090-1092.
189. Uy H, Chan PS, Edward R. Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome. Cornea. 2008;27:70-73.
190. You IC, Kang IS, Lee SH, et al. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. Acta Ophthalmol. 2009;87:653-658.
191. Chévez-Barrios P. Are we getting closer to prevention and treatment of corneal neovascularization? Clin Experiment Ophthalmol. 2007;35: 689-690. (Pubitemid 350090521)
192. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333:328-335. (Pubitemid 40848295)
193. Jo N, Mailhos C, Ju M, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol. 2006;168:2036-2053. (Pubitemid 43825322)
194. Fernando NH, Hurwitz HI. Targeted therapy of colorectal cancer: clinical experience with bevacimuzab. Oncologist. 2004;9(Suppl 1):11-18. (Pubitemid 38747843)
195. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacimuzab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60-65.
196. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90:1344-1349. (Pubitemid 44702055)
197. Gottsch JD, Akpek EK. Topical cyclosporin stimulates neovascularization in resolving sterile rheumatoid central corneal ulcers. Trans Am Ophthalmol Soc. 2000;98:81-87; discussion 87-90.
198. Heiligenhaus A, Steuhl KP. Treatment of HSV-1 stromal keratitis with topical cyclosporin A: a pilot study. Graefes Arch Clin Exp Ophthalmol. 1999;237:435-438. (Pubitemid 29187133)
199. Lipman RM, Epstein RJ, Hendricks RL. Suppression of corneal neovascularization with cyclosporine. Arch Ophthalmol. 1992;110: 405-407.
200. Belin MW, Bouchard CS, Frantz S, et al. Topical cyclosporine in highrisk corneal transplants. Ophthalmology. 1989;96:1144-1150. (Pubitemid 19196060)
201. Benelli U, Ross JR, Nardi M, et al. Corneal neovascularization induced by xenografts or chemical cautery. Inhibition by cyclosporin A. Invest Ophthalmol Vis Sci. 1997;38:274-282. (Pubitemid 27085683)
202. Bourges JL, Lallemand F, Agla E, et al. Evaluation of a topical cyclosporine A prodrug on corneal graft rejection in rats. Mol Vis. 2006; 12:1461-1466. (Pubitemid 46117008)
203. Herbort CP, Matsubara M, Nishi M, et al. Penetrating keratoplasty in the rat: a model for the study of immunosuppressive treatment of graft rejection. Jpn J Ophthalmol. 1989;33:212-220. (Pubitemid 19175114)
204. Hunter PA, Wilhelmus KR, Rice NSC, et al. Cyclosporin-A applied topically to the recipient eye inhibits corneal graft rejection. Clin Exp Immunol. 1981;45:173-177. (Pubitemid 11072458)
205. Kana JH, Hoffman F, Buchen R, et al. Rabbit corneal allograft survival following administration of cyclosporin-A. Invest Ophthalmol Vis Sci. 1982;22:686-690. (Pubitemid 12075376)
206. Maske R, Hill JC, Horak S. Mixed lymphocyte culture responses in rabbits undergoing corneal grafting and topical cyclosporine treatment. Cornea. 1994;13:324-330. (Pubitemid 24198013)
207. Poon A, Constantinou M, Lamoureux E, et al. Topical cyclosporin A in the treatment of acute graft rejection: a randomized controlled trial. Clin Experiment Ophthalmol. 2008;36:415-421.
208. Rehany U, Waisman M. Suppression of corneal allograft rejection by systemic cyclosporine-A in heavily vascularized rabbit corneas following alkali burns. Cornea. 1994;13:447-453. (Pubitemid 24260320)
209. Salisbury JD, Gebhardt BM. Suppression of corneal allograft rejection by cyclosporin A. Arch Ophthalmol. 1981;99:1640-1643. (Pubitemid 11014341)
210. Williams KA, Grutzmacher RD, Roussel TJ, et al. A comparison of the effects of topical cyclosporine and topical steroid on rabbit corneal graft rejection. Transplant. 1985;39:242-244. (Pubitemid 15137814)
211. Nirankari VS. Laser photocoagulation for corneal stromal vascularization. Trans Am Ophthalmol Soc. 1992;90:595-669.
212. Kachi S, Hirano K, Takesue Y, et al. Unusual corneal deposit after the topical use of cyclosporine as eyedrops. Am J Ophthalmol. 2000;130: 667-669.
213. Sonmez B, Beden U, Erkan D. Regression of severe corneal stromal neovascularization with topical cyclosporine 0.05% after penetrating keratoplasty for fungal corneal ulcer. Int Ophthalmol. 2009;29: 123-125.
214. Borras T. Recent developments in ocular gene therapy. Exp Eye Res. 2003;76:643-652. (Pubitemid 36549021)
215. George AJT, Arancibia-Carcamo CV, Awad HM, et al. Gene delivery to the corneal endothelium. Am J Respir Crit Care Med. 2000;162: S194-S200.
216. Jun AS, Larkin DF. Prospects for gene therapy in corneal disease. Eye. 2003;17:906-911. (Pubitemid 37541043)
217. Soler-Andrieu C, Bejjani RA, Bizemont T, et al. Ocular gene therapy: a review of non-viral strategies. Mol Vis. 2006;12:1334-1347. (Pubitemid 44725596)
218. Williams KA, Jessup CF, Coster DJ. Gene therapy approaches to prolonging corneal allograft survival. Expert Opin Biol Ther. 2004;4: 1059-1071. (Pubitemid 38937549)
219. Cavazzano-Calvo M, Thrasher A, Mavillo F. The future of gene therapy. Nature. 2004;427:779-781. (Pubitemid 38297723)
220. Hacein-Bey-Abina S, Le Diest F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002;346:1185-1193. (Pubitemid 34984579)
221. Marshall E. Gene therapy death prompts a review of adenovirus vector. Science. 1999;286:2244-2245. (Pubitemid 30016842)
222. Provost N, Le Meur G, Weber M, et al. Biodistribution of rAAV vectors following intraocular administration: evidence for the presence and persistence of vector DNA in the optic nerve and in the brain. Mol Ther. 2005;11:275-283.
223. Sledz CA, Holko M, de Veer MJ, et al. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol. 2003;5:834-839. (Pubitemid 37087172)
224. Sledz CA, Williams BR. RNA interference and double-stranded-RNAactivated pathways. Biochem Soc Trans. 2004;32(pt 6):952-956.
225. Baer JC, Nirankari VS. Corneal argon laser photocoagulation for the treatment of stromal neovascularization. Surg Forum. 1987;38: 523-526. (Pubitemid 18094410)
226. Cherry PM, Faulkner JD, Shaver RP, et al. Argon laser treatment of corneal neovascularization. Ann Ophthalmol. 1973;5:911-920.
227. Jerold Gordon Y, Mann RK, Mah TS, et al. Fluorescein-potentiated argon laser therapy improves symptoms and appearance of corneal neovascularization. Cornea. 2002;21:770-773. (Pubitemid 35239497)
228. Lim KJ,Wee WR, Lee JH. Treatment of corneal neovascularization with argon laser. Korean J Ophthalmol. 1993;7:25-27.
229. Marsh RJ, Marshall J. Treatment of lipid keratopathy with the argon laser. Br J Ophthalmol. 1982;66:127-135. (Pubitemid 12166864)
230. Marsh RJ. Argon laser treatment of lipid keratopathy. Br J Ophthalmol. 1988;72:900-904. (Pubitemid 19022864)
231. Marsh RJ. Lasering of lipid keratopathy. Trans Ophthalmol Soc U K. 1982;102(pt 1):154-156. (Pubitemid 13248678)
232. Peter J, Fraenkel G, Goggin M, et al. Fluorescein angiographic monitoring of corneal vascularization in lipid keratopathy. Clin Exp Ophthalmol. 2004;32:78-80. (Pubitemid 38344290)
233. Sheppard JD Jr, Epstein RJ, Lattanzio FA Jr, et al. Argon laser photodynamic therapy of human corneal neovascularization after intravenous administration of dihematoporphyrin ether. Am J Ophthalmol. 2006;141:524-529.
234. Staffileno BA. Laser treatment of corneal vessels. Ophthalmology. 1999; 99:1641.
235. Cherry PM, Garner A. Corneal neovascularization treated with argon laser. Br J Ophthalmol. 1976;60:464-472.
236. Epstein RJ, Strutling RD, Hendricks RL, et al. Corneal neovascularization: pathogenesis and inhibition. Cornea. 1987;6:250-257.
237. Pai VH, Handary SV. Necrotizing scleritis following laser therapy for corneal vascularization. Ann Ophthalmol. 2009;41:50-51.
238. Baer JC, Foster CS. Corneal laser photocoagulation for treatment of neovascularization. Efficacy of 577 nm yellow dye laser. Ophthalmology. 1992;99:173-179.
239. Mosier MA, Champion J, Liaw JH, et al. Retinal effects of frequency doubled nd:YAG (532 nm) laser: histopathological comparision with argon laser. Laser Surg Med. 1985;5:377-404. (Pubitemid 15071135)
240. Hemady RK, Baer JC, Foster CS. Biomicroscopic and histopathologic observations after corneal laser photocoagulation in a rabbit model of corneal neovascularization. Cornea. 1993;12:185-190. (Pubitemid 23137857)
241. Sharma A, Samal A, Narang S, et al. Frequency doubled Nd:YAG (532 nm) laser photocoagulation in corneal vascularization: efficacy and time sequenced changes. Indian J Ophthalmol. 2001;49:235-240.
242. Parsa CF, Temprano J, Wilson D, et al. Hemorrhage complicating YAG laser feeder vessel coagulation of cornea vascularization. Cornea. 1994; 13:264-268. (Pubitemid 24129163)
243. Krasnick NM, Spigelman AV. Comparison of yellow dye, continuous wave Nd:YAG, and argon green laser on experimentally induced corneal neovascularization. J Refract Surg. 1995;11:45-49.
244. Goto S. Q-switched Nd:YAG laser treatment for corneal neovascularization. Jpn J Ophthalmol. 1992;36:291-300.
245. Gomer CJ, Ferrario A, Hayashi N, et al. Molecular, cellular, and tissue responses following photodynamic therapy. Laser SurgMed. 1988;8:450-463. (Pubitemid 18260128)
246. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol. 1992;55:145-157.
247. Randleman JB, Stulting RD. Prevention and treatment of corneal graft rejection: current practice patterns. Cornea. 2006;25:286-290.
248. Reed MW, Miller FN, Wieman TJ, et al. The effect of photodynamic therapy on the microcirculation. J Surg Res. 1988;45:452-459. (Pubitemid 18260086)
249. Fankhauser F, Kwasniewska S, Zypen E van der. Basic mechanisms underlying laser throbogenesis in the vascular structures of the eye. Laser Light Ophthalmol. 1989;2:223-231. (Pubitemid 19144411)
250. Ochsner M. Photophysical and photobiological processes in the photodynamic therapy of tumours. J Photochem Photobiol. 1997;39:1-18. (Pubitemid 27285576)
251. Brooks BJ, Ambati BK, Macrus DM, et al. Photodynamic therapy for corneal neovascularization and lipid degeneration. Br J Ophthalmol. 2004;88:840. (Pubitemid 38725605)
252. Fossarello M, Peiretti E, Zucca I, et al. Photodynamic therapy of corneal neovascularization with verteporfin. Cornea. 2003;22:485-488. (Pubitemid 36759046)
253. Yoon KC, You IC, Kang IS, et al. Photodynamic therapy with verteporfin for corneal neovascularization. Am J Ophthalmol. 2007;144:390-395.
254. Gordon YJ, Mann RK, Mah TS, et al. Fluorescein-potentiated argon laser therapy improves symptoms and appearance of corneal neovascularization. Cornea. 2002;21:770-773. (Pubitemid 35239497)
255. Sang-Chul Park, Jae-Ho Kim. Effects of laser photocoagulation on corneal neovascularization in rabbits. J Cataract Refract Surg. 1994:10; 631-639.
256. Corrent G, Roussel TJ, Tseng SCG, et al. Promotion of graft survival by photothrombotic occlusion of corneal neovascularization. Arch Ophthalmol. 1989;107:1051-1056.
257. Treatment of Age Related Macular Degenration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trial-TAP report. Arch Ophthalmol. 1999;117:1329-1345.
258. Wertheim MS, Cook SD, Knox-Cartwright NE, et al. Electrolysis-needle cauterization of corneal vessels in patients with lipid keratopathy. Cornea. 2007;26:230-231. (Pubitemid 46168300)